Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PEMBRO-RT
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2018.
- 27 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.